Skip to main content

Howe Jill Ann's Form 4 filing

Lineage Cell Therapeutics, Inc.LCTX · filed Nov 16, 2026

Accession no.
0001193125-26-463787
Filed
Nov 16, 2026, 5:00 PM ET
Trade date
Nov 16, 2026
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $17.1K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Howe Jill AnnCIK 0001892397Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2026Common SharesPPurchaseAcquired+20,000$0.855F1+$17,10045,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.84 to $0.94 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)